A Case of Abdominal Incisional Bladder Hernia.

The case is a woman in her 60s. She had been aware of lower abdominal distention and pain for six months but was under observation. Gradually, the patient experienced worsening pain during distention and became aware of distention, especially before urination.

Randomised phase III study of S-1 alone versus S-1 plus lentinan for unresectable or recurrent gastric cancer (JFMC36-0701).

Background: Lentinan (LNT) is a purified β-1, 3-glucan that augments immune responses. The present study was conducted to assess the efficacy of LNT in combination with S-1 as a first-line treatment for unresectable or recurrent gastric cancer.

Patients And Methods: Eligible patients were randomly assigned to receive S-1 alone or S-1 plus LNT.

[A case of metachronous liver metastasis from gastric cancer treated with multidisciplinary therapy including hepatectomy].

A 73-year-old man underwent a distal gastrectomy with dissection of D2 lymph nodes for type 2 gastric cancer at the front wall of pyloric antrum in June 2006 (Pathological finding was moderately differentiated adenocarcinoma, T2, N0, H0, P0, M0, fStage IB). Although he was given UFT and PSK for postoperative adjuvant therapy, MRI showed a liver metastasis at segment 6 of the liver in June 2007. After 2 courses of S-1, posterior segmentectomy of the liver was performed.

Efficacy of orally administered superfine dispersed lentinan (beta-1,3-glucan) for the treatment of advanced colorectal cancer.

Background: Lentinan (LNT) is an immune adjuvant medicine for advanced gastric cancer in Japan. Recently, an oral formulation of superfine dispersed lentinan (SDL) has become clinically available. To investigate the safety and effectiveness of SDL, a multi center clinical study in patients with advanced colorectal cancer was conducted.